Phase III Study Comparing Standard Radiotherapy With or Without Weekly Oxaliplatin in Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Preliminary Results
- 20 November 2005
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (33) , 8461-8468
Abstract
Purpose: A prospective, randomized, phase III study was performed to evaluate the feasibility and efficacy of concurrent weekly oxaliplatin with radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (NPC). Patients and Methods: From January 2001 to January 2003, 115 patients with locoregionally advanced NPC were randomly assigned to either radiotherapy (RT) alone (56 patients) or concurrent chemoradiotherapy (CCRT; 59 patients). All patient characteristics were well balanced in both arms. CCRT with oxaliplatin 70 mg/m2 weekly was administered for six doses from the first day of RT. Results: All patients were eligible for toxicity and response analysis. Compliance with the protocol treatment was excellent, with 97% of patients completing all planned doses of oxaliplatin, and a lack of high-grade toxicity was observed. After a median follow-up time of 24 months, there was a significant difference in overall survival (OS), relapse-free survival (RFS), and metastasis-free survival (MFS) in favor of the CCRT arm. The 2-year OS rates were 100% for the CCRT arm and 77% for the RT arm (P = .01). The 2-year MFS rates were 92% for the CCRT arm and 80% for the RT arm (P = .02). The 2-year RFS rates were 96% for the CCRT arm and 83% for the RT arm (P = .02). Conclusion: CCRT with weekly oxaliplatin is feasible and improves OS, MFS, and RFS rates in patients with locoregionally advanced NPC. Therefore, further randomized trials including oxaliplatin are warranted.Keywords
This publication has 39 references indexed in Scilit:
- Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: A phase II study of the Southern Italy Cooperative Oncology Group (SICOG)Annals of Oncology, 2001
- Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinomaAnnals of Oncology, 1999
- Phase I/II study of the CAPABLE regimen for patients with poorly differentiated carcinoma of the nasopharynx.Journal of Clinical Oncology, 1998
- The role of chemotherapy in the management of nasopharyngeal carcinomaCancer, 1998
- Chemotherapy with Cisplatin and Continuous Infusion of 5-Fluorouracil and Bleomycin for Recurrent and Metastatic Nasopharyngeal Carcinoma in TaiwanOncology, 1993
- Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976–1985: Overall survival and patterns of failureInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1992
- Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx. A review of the princess margaret hospital experienceCancer, 1991
- Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouracil.Journal of Clinical Oncology, 1991
- Radiation therapy of nasopharyngeal carcinoma: Prognostic factors based on a 10-year follow-up of 1302 patientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1989
- Excellent Response to cis-Platinum–Based Chemotherapy in Patients with Recurrent or Previously Untreated Advanced Nasopharyngeal CarcinomaAmerican Journal of Clinical Oncology, 1988